| Date Filed | Type | Description |
| 08/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2023 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/14/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/15/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/16/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2022 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/15/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/16/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/17/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/16/2021 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/16/2020 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/14/2020 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/15/2020 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/14/2020 |
SC 13G/A
| TYNDALL CAPITAL PARTNERS L P reports a |
| 02/14/2020 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/18/2019 |
SC 13G/A
| TYNDALL CAPITAL PARTNERS L P reports a 6.1% stake in Onconova Therapeutics, INC. |
| 11/14/2019 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 09/26/2019 |
4
| TYNDALL CAPITAL PARTNERS L P (10% Owner) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Sold 16,700 shares
@ $1.19, valued at
$19.9k
|
|
| 09/24/2019 |
4
| TYNDALL CAPITAL PARTNERS L P (10% Owner) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Sold 75,119 shares
@ $1.6165, valued at
$121.4k
Sold 37,242 shares
@ $1.2343, valued at
$46k
|
|
| 09/20/2019 |
4
| TYNDALL CAPITAL PARTNERS L P (10% Owner) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Sold 49,995 shares
@ $2.1005, valued at
$105k
|
|
| 09/13/2019 |
4
| TYNDALL CAPITAL PARTNERS L P (10% Owner) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Sold 1,247 shares
@ $2.7526, valued at
$3.4k
|
|
| 09/11/2019 |
4
| TYNDALL CAPITAL PARTNERS L P (10% Owner) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Sold 400 shares
@ $2.765, valued at
$1.1k
|
|
| 09/09/2019 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 08/14/2019 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 07/11/2019 |
4
| TYNDALL CAPITAL PARTNERS L P (10% Owner) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Sold 8,185 shares
@ $2.835, valued at
$23.2k
Sold 2,742 shares
@ $2.807, valued at
$7.7k
|
|
| 07/01/2019 |
4
| TYNDALL CAPITAL PARTNERS L P (10% Owner) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Sold 1,458 shares
@ $3.4465, valued at
$5k
|
|
| 06/27/2019 |
4
| TYNDALL CAPITAL PARTNERS L P (10% Owner) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Sold 1,380 shares
@ $3.3976, valued at
$4.7k
|
|
| 05/15/2019 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 02/25/2019 |
SC 13G/A
| TYNDALL CAPITAL PARTNERS L P reports a 14.8% stake in Onconova Therapeutics, INC. |
| 02/14/2019 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 11/14/2018 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 08/14/2018 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/15/2018 |
13F-HR
| Form 13F-HR - Quarterly report filed by institutional managers, Holdings: |
| 05/01/2018 |
4
| TYNDALL CAPITAL PARTNERS L P (10% Owner) has filed a Form 4 on Onconova Therapeutics, Inc.|
Txns:
| Bought 10,147,058 shares
@ $0.425, valued at
$4.3M
Bought 10,147,058 options to buy
@ $0 |
|
|